Publicacións nas que colabora con Alvaro Ruibal Morell (9)

2022

  1. Immunohistochemical expression of VEGFR1 in non small cell lung carcinomas: Lower VEGFR1 expression is asociated with squamous cell carcinoma subtype and high max SUV values in 18F-FDG PET

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 41, Núm. 1, pp. 28-31

2020

  1. 3D printed tacrolimus rectal formulations ameliorate colitis in an experimental animal model of inflammatory bowel disease

    Biomedicines, Vol. 8, Núm. 12, pp. 1-19

  2. Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

    World Journal of Gastroenterology, Vol. 26, Núm. 13, pp. 1513-1524

2019

  1. Evaluation of the therapeutic activity of melatonin and resveratrol in Inflammatory Bowel Disease: A longitudinal PET/CT study in an animal model

    International Journal of Pharmaceutics, Vol. 572

2018

  1. Longitudinal PET/CT evaluation of TNBS-induced inflammatory bowel disease rat model

    International Journal of Pharmaceutics, Vol. 549, Núm. 1-2, pp. 335-342

2016

  1. HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme

    Molecular Neurobiology, Vol. 53, Núm. 3, pp. 1802-1807

2014

  1. Pancreatic ductal adenocarcinoma: Implications of epigenetic role related the src pathway

    Journal of Cancer Science and Therapy, Vol. 6, Núm. 2, pp. 045-051

2009

  1. Egfr expression correlates with maximum standardized uptake value of 18- fluorodeoxyglucose-pet in squamous cell lung Carcinoma

    Current Radiopharmaceuticals, Vol. 2, Núm. 3, pp. 175-176

  2. La expresión inmunohistoquímica intensa de ciclooxigenasa 2 se asocia inversamente con los valores máximos de SUV en la 18F-FDG-PET de pacientes afectados de carcinomas no microcíticos de pulmón. Relación con otros factores biológicos

    Revista española de medicina nuclear, Vol. 28, Núm. 1, pp. 11-14